With new whistleblower rules coming to Wall Street, the industry's lobbyists have mounted a furious behind-the-scenes effort to constrain the reach of the new protections.
Two men, including a Wall Street veteran and a Minnesota trader who went undercover, explain how they worked with the IRS and FBI to expose tax fraud.
This is the story of the most successful—and least known—whistleblower operation of all time. Four men who have made a vast fortune blowing the whistle on the drug industry, forcing Big Pharma to pay the federal government over a billion dollars in settlements.
Bradley Birkenfeld once lived the high life as secret Swiss banker at UBS in Geneva. Then he delivered some of the world’s best-kept secrets to the US government, expecting a great reward. And now he sits in federal prison in Pennsylvania.
Cheryl Eckard became the largest individual whistleblower award recipient ever, hauling in a $96 million bounty as her reward for providing information to the government about manufacturing problems at GlaxoSmithKline.
Have you ever been tempted to blow the whistle on something suspicious you've witnesses in the workplace? Take our poll and share your opinion.
Forget what you think you know about lone whistleblowers taking on giant corporations all by themselves. These days, there's a cottage industry to support—and profit from—whistleblowing.
That promise of cash is providing a new incentive for employees to reveal wrongdoing in their companies. What would you do?
Wall Street is suddenly paying attention to the culture of whistleblowing, because the new Dodd-Frank financial reform law, for the first time, extends whistleblower provisions to Wall Street, meaning employees who expose fraud and wrongdoing stand to collect between 10 and 30 percent of the amount recovered by the government.
Taking a look at the biggest fraud cases of all time, and you're left with just one question: What's wrong with the pharmaceutical industry?
The Food and Drug Administration will announce new rules for how it intends to license orthopedic players—specifically for hip, knee and and spine products.
Latin America is a “very underestimated area of opportunity” for business, Chris Viehbacher, CEO of the drugmaker Sanofi-Aventis, told CNBC Tuesday.
The Food and Drug Administration helped Arizona and California obtain a quick overseas source of a hard-to-find execution drug even as the agency declared it would not regulate or block imports, records show.
The Food and Drug Administration says it must review tobacco products that were introduced or changed after February 2007 in order for companies to keep selling them.
Obama is getting a chance to allay people's fears about the safety of their food. He is set to sign a $1.4 billion overhaul of the food safety system, giving Washington new power to increase inspections at food processing facilities and force companies to recall tainted products.
Swiss pharmaceuticals giant Roche said it would appeal a decision by the US Food and Drug Administration to remove the approval for the drug’s indication for metastatic breast cancer, but analysts doubt the appeal would be successful.
Investors sent shares of diet drug makers soaring Wednesday, one day after an FDA advisory panel recommended approval of Orexigen Therapeutic's weight loss drug Contrave.
Newly released documents detail 12 years of fits and starts at the Securities and Exchange Commission as financier Allen Stanford was allegedly running a global Ponzi scheme.
Federal regulators are expected to move to ban caffeinated alcoholic drinks as soon as this week, according to a New York senator.